1. Home
  2. ADPT vs PRCT Comparison

ADPT vs PRCT Comparison

Compare ADPT & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$16.15

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Logo PROCEPT BioRobotics Corporation

PRCT

PROCEPT BioRobotics Corporation

HOLD

Current Price

$30.84

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADPT
PRCT
Founded
2009
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.0B
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
ADPT
PRCT
Price
$16.15
$30.84
Analyst Decision
Strong Buy
Buy
Analyst Count
10
9
Target Price
$16.60
$51.13
AVG Volume (30 Days)
2.8M
1.4M
Earning Date
02-10-2026
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$252,754,000.00
$299,907,000.00
Revenue This Year
$50.81
$48.30
Revenue Next Year
$1.17
$29.44
P/E Ratio
N/A
N/A
Revenue Growth
42.57
50.07
52 Week Low
$5.96
$27.80
52 Week High
$20.76
$89.49

Technical Indicators

Market Signals
Indicator
ADPT
PRCT
Relative Strength Index (RSI) 46.73 40.19
Support Level $16.05 $31.78
Resistance Level $16.82 $32.94
Average True Range (ATR) 0.60 1.46
MACD -0.03 -0.40
Stochastic Oscillator 42.26 3.09

Price Performance

Historical Comparison
ADPT
PRCT

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

About PRCT PROCEPT BioRobotics Corporation

PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.

Share on Social Networks: